Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

doi:10.1136/annrheumdis-2020-217424

. 2020 May;79(5):667-668.

doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Sara Monti¹, Silvia Balduzzi², Paolo Delvino³, Elisa Bellis³, Verdiana Serena Quadrelli³, Carlomaurizio Montecucco³

Affiliations

¹ Rheumatology Department, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy sara.saramonti@gmail.com.
² Rheumatology Department, IRCCS Policlinico San Matteo, Pavia, Italy.
³ Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

PMID: 32241793
PMCID: PMC7211079
DOI: 10.1136/annrheumdis-2020-217424

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Sara Monti et al. Ann Rheum Dis. 2020 May.

. 2020 May;79(5):667-668.

doi: 10.1136/annrheumdis-2020-217424. Epub 2020 Apr 2.

Authors

Sara Monti¹, Silvia Balduzzi², Paolo Delvino³, Elisa Bellis³, Verdiana Serena Quadrelli³, Carlomaurizio Montecucco³

Affiliations

¹ Rheumatology Department, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy sara.saramonti@gmail.com.
² Rheumatology Department, IRCCS Policlinico San Matteo, Pavia, Italy.
³ Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

PMID: 32241793
PMCID: PMC7211079
DOI: 10.1136/annrheumdis-2020-217424

No abstract available

Keywords: antirheumatic agents; arthritis, rheumatoid; biological therapy; spondylitis, ankylosing.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment in

SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment.
Joob B, Wiwanitkit V. Joob B, et al. Ann Rheum Dis. 2020 Jun;79(6):e61. doi: 10.1136/annrheumdis-2020-217506. Epub 2020 Apr 15. Ann Rheum Dis. 2020. PMID: 32295787 No abstract available.
Dealing with COVID-19 in a Pediatric Rheumatology Unit in Italy.
Costi S, Caporali R, Cimaz R. Costi S, et al. Paediatr Drugs. 2020 Jun;22(3):263-264. doi: 10.1007/s40272-020-00395-2. Paediatr Drugs. 2020. PMID: 32297225 Free PMC article. No abstract available.
Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India.
Gupta L, Misra DP, Agarwal V, Balan S, Agarwal V. Gupta L, et al. Ann Rheum Dis. 2021 Jan;80(1):e1. doi: 10.1136/annrheumdis-2020-217509. Epub 2020 Apr 16. Ann Rheum Dis. 2021. PMID: 32299795 No abstract available.
Antirheumatic agents in covid-19: is IL-6 the right target?
Capecchi PL, Lazzerini PE, Volterrani L, Mazzei MA, Rossetti B, Zanelli G, Bennett D, Bargagli E, Franchi F, Cameli M, Valente S, Cantarini L, Frediani B. Capecchi PL, et al. Ann Rheum Dis. 2021 Jan;80(1):e2. doi: 10.1136/annrheumdis-2020-217523. Epub 2020 Apr 16. Ann Rheum Dis. 2021. PMID: 32299796 No abstract available.
COVID-19 and rheumatology: first steps towards a different future?
McInnes IB. McInnes IB. Ann Rheum Dis. 2020 May;79(5):551-552. doi: 10.1136/annrheumdis-2020-217494. Ann Rheum Dis. 2020. PMID: 32299844 No abstract available.
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.
Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, Jung B, Larcher R, Klouche K, Le Moing V. Guilpain P, et al. Ann Rheum Dis. 2021 Jan;80(1):e10. doi: 10.1136/annrheumdis-2020-217549. Epub 2020 Apr 20. Ann Rheum Dis. 2021. PMID: 32312768 No abstract available.
Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID).
Giollo A, Adami G, Gatti D, Idolazzi L, Rossini M. Giollo A, et al. Ann Rheum Dis. 2021 Feb;80(2):e12. doi: 10.1136/annrheumdis-2020-217598. Epub 2020 Apr 22. Ann Rheum Dis. 2021. PMID: 32321720 No abstract available.
Myositis as a manifestation of SARS-CoV-2.
Beydon M, Chevalier K, Al Tabaa O, Hamroun S, Delettre AS, Thomas M, Herrou J, Riviere E, Mariette X. Beydon M, et al. Ann Rheum Dis. 2021 Mar;80(3):e42. doi: 10.1136/annrheumdis-2020-217573. Epub 2020 Apr 23. Ann Rheum Dis. 2021. PMID: 32327427 No abstract available.
Novel COronaVirus Disease 2019 (COVID-19) epidemic: What are the risks for systemic sclerosis patients?
Del Papa N, Sambataro G, Minniti A, Pignataro F, Caporali R. Del Papa N, et al. Autoimmun Rev. 2020 Jul;19(7):102558. doi: 10.1016/j.autrev.2020.102558. Epub 2020 May 5. Autoimmun Rev. 2020. PMID: 32380317 Free PMC article. No abstract available.
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs.
Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, Gentileschi S, Bennett D, Falsetti P, Lanzarone N, Bellisai F, Barreca C, D'Alessandro R, Cantarini L, Frediani B. Conticini E, et al. Ann Rheum Dis. 2021 Feb;80(2):e14. doi: 10.1136/annrheumdis-2020-217681. Epub 2020 May 15. Ann Rheum Dis. 2021. PMID: 32414804 No abstract available.
COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy.
Benoy S, Traksel R, Verhaegh P, Broen J. Benoy S, et al. Ann Rheum Dis. 2021 Mar;80(3):e44. doi: 10.1136/annrheumdis-2020-217765. Epub 2020 Jun 3. Ann Rheum Dis. 2021. PMID: 32493726 No abstract available.
COVID-19 infection in a patient with FMF: does colchicine have a protective effect?
Kobak S. Kobak S. Ann Rheum Dis. 2021 Mar;80(3):e39. doi: 10.1136/annrheumdis-2020-217882. Epub 2020 Jun 5. Ann Rheum Dis. 2021. PMID: 32503853 No abstract available.
Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.
Monti S, Montecucco C. Monti S, et al. Ann Rheum Dis. 2021 Mar;80(3):e40. doi: 10.1136/annrheumdis-2020-217957. Epub 2020 Jun 5. Ann Rheum Dis. 2021. PMID: 32503855 No abstract available.
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Schulze-Koops H, et al. Ann Rheum Dis. 2021 May;80(5):e67. doi: 10.1136/annrheumdis-2020-218075. Epub 2020 Jun 26. Ann Rheum Dis. 2021. PMID: 32591357 No abstract available.
Rheumatic disease and COVID-19.
Liew JW, Graef ER. Liew JW, et al. Ann Rheum Dis. 2021 Mar;80(3):e43. doi: 10.1136/annrheumdis-2020-217674. Epub 2020 Jul 10. Ann Rheum Dis. 2021. PMID: 32651196 No abstract available.
COVID-19 and Behçet's disease: clinical case series.
Espinosa G, Araujo O, Amaro S, Bodro M, Moreno PJ, Moreno R, Ugarte A, Cervera R. Espinosa G, et al. Ann Rheum Dis. 2021 Mar;80(3):e41. doi: 10.1136/annrheumdis-2020-217778. Epub 2020 Jul 21. Ann Rheum Dis. 2021. PMID: 32719040 No abstract available.
Impact of the COVID-19 lockdown on the management and control of patients with GCA.
Praliaud R, Greigert H, Samson M, Zeller M, Boulin M, Bielefeld P, Ramon A, Cottin Y, Bonnotte B. Praliaud R, et al. Ann Rheum Dis. 2021 Jun;80(6):e102. doi: 10.1136/annrheumdis-2020-218360. Epub 2020 Aug 7. Ann Rheum Dis. 2021. PMID: 32769157 No abstract available.

Cited by

Effects of the COVID-19 Pandemic on Patients Living With Vasculitis.
Banerjee S, George M, Young K, Venkatachalam S, Gordon J, Burroughs C, Curtis D, Ferrada M, Gavigan K, Grayson PC, Kullman J, Danila MI, Curtis JR, Shaw DG, Benjamin Nowell W, Merkel PA; Vasculitis Patient‐Powered Research Network. Banerjee S, et al. ACR Open Rheumatol. 2021 Jan;3(1):17-24. doi: 10.1002/acr2.11204. Epub 2020 Dec 8. ACR Open Rheumatol. 2021. PMID: 33784021 Free PMC article.
COVID-19 in patients with gout on colchicine.
Pelechas E, Drossou V, Voulgari PV, Drosos AA. Pelechas E, et al. Rheumatol Int. 2021 Aug;41(8):1503-1507. doi: 10.1007/s00296-021-04902-7. Epub 2021 Jun 5. Rheumatol Int. 2021. PMID: 34089357 Free PMC article. Review.
The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study.
Ziadé N, Hmamouchi I, El Kibbi L, Abdulateef N, Halabi H, Abutiban F, Hamdi W, El Rakawi M, Eissa M, Masri B. Ziadé N, et al. Clin Rheumatol. 2020 Nov;39(11):3205-3213. doi: 10.1007/s10067-020-05428-2. Epub 2020 Sep 30. Clin Rheumatol. 2020. PMID: 32996071 Free PMC article.
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.
Jessica Chang TY, Pope JE. Jessica Chang TY, et al. Immunotherapy. 2020 Oct;12(15):1115-1119. doi: 10.2217/imt-2020-0153. Epub 2020 Jul 9. Immunotherapy. 2020. PMID: 32640861 Free PMC article. No abstract available.
Clinical impact of COVID-19 on a French population of spondyloarthritis patients.
Roux CH, Brocq O, Gerald F, Pradier C, Bailly L. Roux CH, et al. Clin Rheumatol. 2020 Nov;39(11):3185-3187. doi: 10.1007/s10067-020-05413-9. Epub 2020 Sep 24. Clin Rheumatol. 2020. PMID: 32970219 Free PMC article. No abstract available.

See all "Cited by" articles

References

1. Memoli MJ, Athota R, Reed S, et al. . The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014;58:214–24.10.1093/cid/cit725 - DOI - PMC - PubMed
1. Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther 2018;16:781–91.10.1080/14787210.2018.1521270 - DOI - PubMed
1. D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl 2020. doi:10.1002/lt.25756 - DOI - PubMed
1. Shi Y, Wang Y, Shao C, et al. . COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;38210.1038/s41418-020-0530-3 - DOI - PMC - PubMed
1. Hui DS, Azhar EI, Kim Y-J, et al. . Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18:e217–27.10.1016/S1473-3099(18)30127-0 - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information

[1] Memoli MJ, Athota R, Reed S, et al. . The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014;58:214–24.10.1093/cid/cit725 - DOI - PMC - PubMed

[2] Memoli MJ, Athota R, Reed S, et al. . The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014;58:214–24.10.1093/cid/cit725 - DOI - PMC - PubMed

[3] Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther 2018;16:781–91.10.1080/14787210.2018.1521270 - DOI - PubMed

[4] Noreña I, Fernández-Ruiz M, Aguado JM. Viral infections in the biologic therapy era. Expert Rev Anti Infect Ther 2018;16:781–91.10.1080/14787210.2018.1521270 - DOI - PubMed

[5] D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl 2020. doi:10.1002/lt.25756 - DOI - PubMed

[6] D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl 2020. doi:10.1002/lt.25756 - DOI - PubMed

[7] Shi Y, Wang Y, Shao C, et al. . COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;38210.1038/s41418-020-0530-3 - DOI - PMC - PubMed

[8] Shi Y, Wang Y, Shao C, et al. . COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020;38210.1038/s41418-020-0530-3 - DOI - PMC - PubMed

[9] Hui DS, Azhar EI, Kim Y-J, et al. . Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18:e217–27.10.1016/S1473-3099(18)30127-0 - DOI - PMC - PubMed

[10] Hui DS, Azhar EI, Kim Y-J, et al. . Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18:e217–27.10.1016/S1473-3099(18)30127-0 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Affiliations

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Authors

Affiliations

Conflict of interest statement

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical